Bio-Rad acquires Ciphergen's instrument business.
Bio-Rad's sales force could provide a new market push for SELDI, however, the company may be betting on the eventual development of diagnostic applications to drive technology sales. The acquisition also gives Bio-Rad access to mass spectrometry and biochip array technologies. In 2005, Ciphergen's product revenues fell 42% to $18.4 million as sales of ProteinChip Systems dropped 54%. Sales of ProteinChip Systems and related products accounted for 82% of revenues last year. (For second quarter results for Bio-Rad and Ciphergen, see page 12.)
|Printer friendly Cite/link Email Feedback|
|Title Annotation:||Executive Briefing: News, Trends & Market Intelligence for Instrument Executives|
|Publication:||Instrument Business Outlook|
|Date:||Aug 15, 2006|
|Previous Article:||The 2006 IBO Industrial Design Awards: style conquers.|
|Next Article:||3M acquires gas detection company.|